New report shows adult vaccination returns up to €23 to society for every €1 spent by Government

If Government fully implements national immunisation programmes for Influenza, Pneumococcal Disease, Herpes Zoster and Respiratory Syncytial Virus there will be a return of up to €23 to society for every €1 spent by Government according to the Office of Health Economics (OHE) Report1

 

  • 73,731 reductions in hospital admissions as a result of implementing preventative adult vaccination1

 

  • Adult vaccination provides up to €4.8 billion in net monetary benefits to society, the equivalent of up to €7,031 for each person’s individual vaccination course1

 

  • 1,429 deaths and 16,555 life years can be saved if National Immunisation Advisory Committee (NIAC) recommended programmes for influenza, Pneumococcal Disease (PD), Herpes Zoster (HZ) and Respiratory Syncytial Virus (RSV) are fully implemented. These programmes would lead to the prevention of approximately 376,000 disease cases.1

 

  • Report calls on policy makers in Ireland to invest more in preventative strategies, including adult immunisation programmes due to the large positive socioeconomic returns.1

 

A new report from the Office of Health Economics (OHE), commissioned by GSK and launched at Leinster House today shows that implementing adult national immunisation programmes for Influenza, Pneumococcal Disease (PD), Herpes Zoster (HZ) and Respiratory Syncytial Virus (RSV) generates societal value worth up to €23 for every €1 spent.

 

Titled ‘The Value of Adult Vaccination in Ireland’, the report reveals there would be 73,731 less hospital admissions and 16,555 life years saved if the Government implemented vaccination programmes recommended by the National Immunisation Advisory Committee (NIAC) for these diseases.1

 

Simon Brassel, Senior Principal Economist at OHE, said: “Adult immunisation programmes in Ireland offset their costs multiple times through benefits to individuals, the healthcare system and wider society and play a crucial role in enabling Irish people to live longer, healthier and better lives. However, coverage and reimbursement decisions are often hampered by an underestimation of their full socioeconomic value. If all the NIAC recommended adult immunisation programmes studied were fully implemented we would see the generation of considerable societal value on top of large health gains for individuals.”

 

The first-of-its-kind report for Ireland highlights that adult immunisation programmes for influenza, pneumococcal disease, herpes zoster, and respiratory syncytial virus would prevent an estimated 375,807 disease cases and would avoid 1,429 deaths from these diseases.1

 

“Polio survivors are a living reminder of the value of vaccinations. Before the polio vaccine was rolled out in Ireland, epidemics in the 40s and 50s left thousands of babies and children either paralysed or requiring years of rehabilitation in hospital to recover. Later in life, Late Effects of Polio, or Post Polio Syndrome put many of us back into wheelchairs, destroying our ability to live independent lives,” said Macrina Clancy, Cathaoirleach, Polio Survivors Ireland.If there had been a polio vaccine for us at the time, we wouldn’t be living with disabilities, chronic pain and a severe intolerance to cold, brought about by polio. Vaccinations have been demonstrated as being hugely effective in keeping people safe and well. If a disease is preventable, we should be doing everything in our power to avoid unnecessary illness, particularly in our older adult populations.”

 

Kate O’Connell, Pharmacist and Director, O’Connell Pharmacy Group, said: “These findings highlight the immense value and positive impact of adult immunisation programmes in Ireland. By investing in these programmes, we not only protect individuals from diseases but also contribute to overall public health and alleviating pressure on our healthcare system. Euro for Euro, vaccination is a highly effective way to alleviate the pressures on our health services and I hope the Government takes on board the compelling data in this report.”